Last reviewed · How we verify

Drug either PPIS or H2RA and prokinetics

King Saud University · FDA-approved active Small molecule

This is a combination therapy using either proton pump inhibitors (PPIs) or histamine-2 receptor antagonists (H2RAs) to reduce gastric acid, paired with prokinetic agents to enhance gastric motility and accelerate gastric emptying.

This is a combination therapy using either proton pump inhibitors (PPIs) or histamine-2 receptor antagonists (H2RAs) to reduce gastric acid, paired with prokinetic agents to enhance gastric motility and accelerate gastric emptying. Used for Gastroesophageal reflux disease (GERD), Peptic ulcer disease, Functional dyspepsia with impaired gastric motility.

At a glance

Generic nameDrug either PPIS or H2RA and prokinetics
Also known asDrug treatment, lansoprazole, esomeprazole,pantoprazole,rebeprazole, omeprazole,cimetidine,nizatidine,famotidine,ranitidine,lafutidine
SponsorKing Saud University
Drug classCombination antacid and prokinetic agent
TargetH+/K+-ATPase (PPIs) or H2 receptor (H2RAs); dopamine antagonist or other prokinetic target
ModalitySmall molecule
Therapeutic areaGastroenterology
PhaseFDA-approved

Mechanism of action

PPIs irreversibly inhibit the H+/K+-ATPase pump in gastric parietal cells, while H2RAs competitively block histamine H2 receptors to reduce acid secretion. Prokinetics (such as metoclopramide or domperidone) enhance gastric muscle contractions and accelerate food movement through the stomach. The combination addresses both acid-related symptoms and motility dysfunction in gastroesophageal reflux disease and related conditions.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results